|Cancer||Genetic Cancer Risk|
|Female Breast||High Risk|
|Male Breast||Elevated Risk|
|Cancer Type||Age Range||Cancer Risk||Risk for General Population|
|Female Breast||To age 503, 4||17%||1.9%|
|To age 803, 4||53%||10.2%|
|Pancreatic||To age 803, 4||2%-3%||1%|
|Ovarian||To age 803, 4||5%||1.0%|
|Male Breast||To age 803, 4||1%||0.1%|
The overview of medical management options provided is a summary of professional society guidelines. The most recent version of each guideline should be consulted for more detailed and up-to-date information before developing a treatment plan for a particular patient.
This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.
|Cancer Type||Procedure||Age to Begin||Frequency |
(Unless otherwise indicated by findings)
|Female Breast||Breast awareness - Women should be familiar with their breasts and promptly report changes to their healthcare provider. Periodic, consistent breast self-examination (BSE) may facilitate breast awareness.5||Individualized||NA|
|Clinical encounter, including clinical breast exam, ongoing risk assessment and risk-reduction counseling5||When genetic risk is identified||Every 6 to 12 months|
|Mammography with consideration of tomosynthesis and breast MRI with contrast6||Age 30, or modified to a younger age based on family history||Annually|
|Consider risk-reducing mastectomy.6||Individualized||NA|
|Consider additional risk-reduction strategies.5, 6||Individualized||NA|
|Pancreatic||For patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in screening for pancreatic cancer, preferably within research protocols.7, 8||Age 50, or 10 years younger than the earliest age of pancreatic cancer diagnosis in the family||Annually|
|Provide education about ways to reduce pancreatic cancer risk, such as not smoking and losing weight.7, 9||Individualized||Individualized|
|Ovarian||Currently there are no specific medical management recommendations for ovarian cancer risk in mutation carriers.||NA||NA|
|Male Breast||Currently there are no specific medical management guidelines for breast cancer risk in mutation carriers. However, the increase in risk warrants consideration of options for male breast cancer screening, such as patient breast awareness education and clinical breast examinations.5, 6||Individualized||NA|
|For Patients With A Cancer Diagnosis||For patients with a gene mutation and a diagnosis of cancer, targeted therapies may be available as a treatment option for certain tumor types (e.g., platinum chemotherapy, PARP-inhibitors)9||NA||NA|
The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the PALB2 gene.
A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.
In rare instances, an individual may inherit mutations in both copies of the PALB2 gene, leading to the condition Fanconi Anemia, Complementation Group N (FANCN). This condition is extremely rare, but is thought to include physical abnormalities, growth retardation, progressive bone marrow failure and a high risk for cancer. The children of this patient are at risk of inheriting FANCN only if the other parent is also a carrier of a PALB2 mutation. Screening the other biological parent of any children for PALB2 mutations may be appropriate.10